Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05958290
Other study ID # H-23029723
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2023
Est. completion date November 30, 2025

Study information

Verified date April 2024
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this non-randomized prospective study is to test whether 6-weeks antibiotic treatment can cure an cardiac implantable electronic device (CIED) infection in patients where device extraction is not feasible. The main question it aims to answer: • Is 6-weeks medical therapy effective in curing definite CIED infection with device retention? Participants will discontinue the antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total. After discontinuation of antibiotics, patients are closely observed for bacterial relapse. For patients who are not interested in participation and who do not have exclusion criteria, we will ask for consent into a registry as we wish to compare patients undergoing discontinuation of antibiotics with patients undergoing standard treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date November 30, 2025
Est. primary completion date November 30, 2025
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Definite CIED infection by the EHRA criteria - Deemed non-eligible for CIED extraction Exclusion Criteria: - Unavailable for follow-up (e.g., tourist)

Study Design


Related Conditions & MeSH terms

  • Cardiac Implantable Electronic Device Infection

Intervention

Other:
Discontinuation of antibiotics
Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen Region Hovedstaden

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite endpoint of death or relapse bacteremia Composite endpoint of all-cause mortality or relapse bacteremia with the primary pathogen 12 months
Secondary Death All-cause mortality. The number of patients who die within 12 months will be assessed for the main study arm as well as the registry study arm through medical chart review. 12 months
Secondary Readmission for any cause The number of patients readmitted for any cause will be examined for the main study arm as well as the registry study arm through medical chart review. 12 months
Secondary Device extraction The number of patients who have their device extracted will be assessed for the main study arm as well as the registry study arm through medical chart review.. 12 months
Secondary Change in quality of life Quality of life will be assessed at inclusion and after 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ) evaluated with a face-to-face interview. We will evaluate changes in KCCQ scores from inclusion to end of follow-up. This outcome will only be assessed for the main study arm. 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06323668 - Cardiac Implantable Electronic Device remOval Versus Full coUrse Medical Treatment N/A
Completed NCT01043705 - TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD N/A
Completed NCT05576194 - Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection
Completed NCT03842124 - Improving Safety of Lead Extraction Procedures by Traction Force Sensing N/A